Anti-inflammatory effects of alkaline phosphatase in coronary artery bypass surgery with cardiopulmonary bypass

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 3, Issue 3, 2009, Pages 214-220

  Kats, Suzanne ^a   Brands, Ruud ^b   Seinen, Willem ^b   de Jager, Wilco ^c   Bekker, Margreet W A ^a   Hamad, Mohamed A Soliman ^a   Tan, M Erwin S H ^a   Schönberger, Jacques P A M ^a  

^a CATHARINA HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Alkaline phosphatase; Cardiopulmonary bypass; Coronary artery bypass grafting; Endotoxin; Inflammatory response

Indexed keywords

ALKALINE PHOSPHATASE; ENDOTOXIN ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANTIINFLAMMATORY ACTIVITY; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; COW; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFLAMMATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALKALINE PHOSPHATASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CARDIOPULMONARY BYPASS; CATTLE; CORONARY ARTERY BYPASS; CYTOKINES; ENDOTOXINS; HUMANS; PATENTS AS TOPIC; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70350760065     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221309789257388     Document Type: Review

References (30)

1. Cremer J, Martin M, Redl H, et al. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996; 61: 1714-1720.
2. Oudemans-Van SHM, Jansen PGM, Hoek FJ, et al. Intestinal permeability, circulating endotoxin, and postoperative systemic responses in cardiac surgery patients. J Cardiothor Vasc Anesth 1996; 2: 187-194.
3. Nilsson L, Kulander L, Nyström SO, et al. Endotoxins in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 100: 777-780.
4. Rocke DA, Graffin SL, Wells MT, et al. Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987; 93: 832-837.
5. Raetz CRH. Biochemistry of endotoxins. Annu Rev Biochem 1990; 59: 129-170.
6. Poelstra K, Bakker WW, Klok PA, et al. A physiologic function for alkaline phosphatase: endotoxin detoxification. Lab Invest 1997; 76(3): 319-327.
7. Bentala H, Verweij WR, Huizinga-Van der Vlag A, et al. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 2002; 18(6): 561-566.
8. Bates JM, Akerlund J, Mittge E, et al. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. Cell Host Microbe 2007; 2(6): 371-382.
9. Beumer C, Wulferink M, Raaben W, et al. Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated disease, attenuates LPS toxicity in mice and piglets. J Pharmacol Exp Ther 2003; 307: 737-744.
10. Pickkers, R.P., Heemskerk, S., Velders, M.P., Raaben, W., Marty W.B.F.: EP1952823A1 (2007).
11. Pickkers RP, Snellen F, Rogiers P, et al. Clinical pharmacology of exogenously administered alkaline phosphatase. Eur J Clin Pharmacol 2009; 65(4): 393-402.
12. Kink, J. A.: US20080206259 (2008).
13. Rothenburger M, Soepawarta R, Deng MC, et al. Prediction of clinical outcome after cardiac surgery: The role of cytokines, endotoxin, and anti-endotoxin core antibodies. Shock 2001; 16(1): 44-50.
14. de Jager W, Prakken BJ, Bijlsma JWJ, et al. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of internering heterofilie antibodies. J Immunol Methods 2005; 300: 124-135.
15. Ramael S. A phase I study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of Calf Intestinal Alkaline Phosphatase 72-h infusions in healthy volunteers. SGS Biopharma Research Unit Stuivenberg, SGS Biopharma B103613 report 2004.
16. Riddington DW, Venkatesh B, Boivin ChM, et al. Intestinal permeability, gastric intramucosa pH and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA 1996; 275: 1007-1012.
17. Brands, R., Poelstra, K.: US2009001091 (2009).
18. Andersen LW, Baek L, Degn H, et al. Presence of circulating endotoxins during cardiac operations. J Thorac Cardiovasc Surg 1987; 93: 115-119.
19. Baue AE. The role of the gut in the development of muliple organ dysfunction in cardiothoracic patients. Ann Thorac Surg 1993; 55: 822-829.
20. Su F, Brands R, Wang Z, et al. Beneficial effects of alkaline phosphatase in septic shock. Crit Care Med 2006; 34(8): 2182-2187.
21. Risnes I, Ueland T, Lundblad R, et al. Changes in the cytokine network and complement parameters during open heart surgery. Interact Cardiovasc Thorac Surg 2003; 2: 19-24.
22. Jansen PG, Te Velthuis H, Oudemans-Van Straaten HM, et al. Perfusion-related factors of endotoxin release during cardiopulmonary bypass. Eur J CardioThorac Surg 1994; 8: 125-129.
23. Gercekoglu H, Tarim O, Agar I, et al. Effects of hypothermia on blood endogenous endotoxin levels during cardiopulmonary bypass. J Card Surg 1997; 12: 223-227.
24. Nashef SAM, Roques RP, Gauducheau S, et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardio-Thorac Surg 1999; 16: 9-13.
25. Bennett-Guerrero E, Ayuso L, Hamilton-Davies C, et al. Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA 1997; 277(8): 646-650.
26. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass surgery. JAMA 2007; 297(7): 471-478.
27. Hill GE, Alonso A, Spurzem JR, et al. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass induced inflammation in humans. J Thorac Cardiovasc Surg 1995; 110: 1658-1662.
28. Defraigne JO, Princemail J, Larbuisson R, et al. Cytokine release and neutrophil activation are not prevented by heparin coated circuits and aprotinin administration. Ann Thorac Surg 2000; 69: 1084-1091.
29. Englberger L, Kipfer B, Berdat PA, et al. Aprotinin in coronary operation withcardiopulmonary bypass: Does low dose aprotinin inhibit the inflammatory response? Ann Thorac Surg 2002; 73: 1897-1904.
30. Ladner, R. C., Ley, A.C.: US20080200646 (2008).